```
(FILE 'HOME' ENTERED AT 10:59:32 ON 23 DEC 1999)
      FILE 'MEDLINE, CAPLUS, BIOSIS, SCISEARCH' ENTERED AT 10:59:58 ON 23 DEC
      1999
         129266 S FIBRIN OR FIBRINOGEN
L1
      75877 S CELL(3A) TRANSFORMATION
L3
          157581 S CELL(3A) TRANSFORM?
L4
             406 S L1 AND L3
L5
            300 S L1(P)L3.
        1990497 S NUCLEIC(W) ACID OR DNA OR POLYNUCLEOTIDE
L6
L7
             36 S L5 AND L6
             24 DUP REM L7 (12 DUPLICATES REMOVED)
\Gamma8
\cdot => s 13(5a)11
            30 L3(5A) L1
L9
=> s 16 and 19
L10
             2 L6 AND L9
=> d 1-2 bib 110
     ANSWER 1 OF 2 CAPLUS COPYRIGHT 1999 ACS
L10
     1996:113481 CAPLUS
AN
     124:137837
DN
     Host cells transformed with fusion protein gene and method for screening
     test samples with receptor-ligand interactions or peptide-binding
     activities
     Young, Kathleen H.; Ozenberger, Bradley A.
PΑ
     American Cyanamid Co., USA
     PCT Int. Appl., 54 pp.
     CODEN: PIXXD2
DT
     Patent
LA
     English
FAN.CNT 1
     PATENT NO.
                      KIND DATE
PΙ
     WO 9534646 A1
                            19951221
                                           WO 1995-US6895
        W: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KG,
            KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MX, NO, NZ, PL, RO, RU,
            SG, SI, SK, TJ, TM, TT, UA, UG, UZ, VN
        RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT,
           LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE,
            SN, TD, TG
    US 5989808
                           19991123
                                          US 1994-259609
                                                           19940614
    CA 2195083
                                          CA 1995-2195083 19950531
                      AA
                          19951221
    AU 9526066
                      A1
                           19960105
                                          AU 1995-26066
                                                           19950531
    AU: 706173
                      B2
                           19990610
    EP 765389
                  A1
                           19970402
                                          EP 1995-920689
                                                           19950531
    R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE
    -ZA 9504892
                 A 19960130
                                          ZA 1995-4892
                                                           19950613
    LT 4230
                      В
                           19971027
                                          LT 1997-4
                                                           19970113
                                                           19970214
    LV 11906
                      В
```

19980620

LV 1997-4

PRAI US 1994-259609 19940614 WO 1995-US6895 19950531

L10 ANSWER 2 OF 2 CAPLUS COPYRIGHT 1999 ACS

AN 1982:46872 CAPLUS

DN 96:46872

TI Revertants of rat cells transformed by avian erythroblastosis virus

AU Quade, Kristina; Saule, Simon; Stehelin, Dominique; Kitchener, Gay; Hayman, Michael J.

CS Imp. Cancer Res. Fund, London, WC2A 3PX, UK

SO Virology (1981), 115(2), 322-33 CODEN: VIRLAX; ISSN: 0042-6822

DT Journal

LA English

=> d ab 1 110

to

L10 ANSWER 1 OF 2 CAPLUS COPYRIGHT 1999 ACS

AB This invention relates to novel modified host cells which express heterologous fused proteins and methods of screening for test samples having peptide-binding activity; wherein the modified host cell comprises:

(a) a gene sequence encoding a heterologous fusion protein; said fusion protein comprising a first peptide of a peptide binding pair, or segment of said first peptide, which is joined to either a DNA binding domain or its corresponding transcriptional activation domain of a transcriptional activation protein; (b) a gene sequence encoding a heterologous fusion protein, said fusion protein comprising a second peptide of the peptide binding pair in (a), or a segment thereof, fused

either a DNA binding domain or its corresponding transcriptional activation domain, whichever one is not employed in (a); (c) a reporter gene operatively assocd. with the transcriptional activation protein, or

portion thereof; (d) optionally, a deletion or mutation in the chromosomal

DNA of the host cell for the transcriptional activation protein if present in the selected host cell.

T 1 0